Exelixis, Inc. (EXEL)

NMS – Real Time Price. Currency in USD

54.77

+1.54 (2.89%)

At close: Jun 26, 2026, 4:00 PM EDT

54.90

+0.13 (0.24%)

After-hours: Jun 26, 2026, 6:09 PM EDT

10.06.2026

Exelixis Hits High on Growing Sales, Institutional Inflows

Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.

09.06.2026

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

04.06.2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

03.06.2026

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

03.06.2026

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

01.06.2026

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Videos

No Data

There is no data to display

Press releases

30.05.2026

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr.

27.05.2026

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

CHEVY CHASE, Md.--(BUSINESS WIRE)-- #Biotech--Caring Men Global, a nonprofit dedicated to supporting male caregivers facing a loved one's cancer, has received a grant from Exelixis to launch “Strong Caregivers, Stronger Survivors,” a caregiver-centered cancer recurrence prevention program designed to prepare men to effectively support cancer survivors following treatment. Survivors are often most vulnerable after active treatment ends, when medical oversight decreases and responsibility for prevention, mo.

21.05.2026

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago. “The presentations at ASCO this year highlight the continued progress of our strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the d.

19.05.2026

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of th.

Exelixis, Inc. (EXEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exelixis, Inc. (EXEL)

Exelixis Hits High on Growing Sales, Institutional Inflows

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Videos

No Data

Press releases

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Exelixis Hits High on Growing Sales, Institutional Inflows

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Videos

No Data

Press releases

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Search stocks

Exelixis, Inc. (EXEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exelixis, Inc. (EXEL)

Exelixis Hits High on Growing Sales, Institutional Inflows

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Videos

No Data

Press releases

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Exelixis Hits High on Growing Sales, Institutional Inflows

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Videos

No Data

Press releases

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer